Exercise as medicine for heart failure

Not Applicable

• Conditions: heart failure; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12619000174189
• Lead Sponsor: The University of western Australia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-02-06
• Last Update Posted: 15 July 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

NYHA Class II-IIIb with systolic dysfunction (HFrEF, EF <40%).
Willing and able to sign written informed consent prior to trial entry
Suitable to participate in a 16-week exercise training program, as determined by the medical history and physical examination

Exclusion Criteria

Current smoking or smoking in the past 12 months,
Renal impairment (stage 4 or 5 CKD),
Exercise-induced ischaemia at a low workload (<3 METS),
Hypertension (>165/95mmHg)
Diagnosed peripheral artery disease

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Changes in aerobic capacity, as assessed by VO2peak.<br>Exercise testing will be performed on a conventional cycle ergometer using 3 minute stages. Heart rate and rhythm and oxygen saturation will be measured continuously by 12-lead ECG and pulse oximeter respectively. Blood pressure, rating of perceived exertion (Borg Scale) and perceived dyspnoea (Borg Scale) will be recorded during the final 30 seconds of each stage. Indirect calorimetry will be measured employing a metabolic analysis system to establish.<br><br>[Assessments will be made prior to, and immediately following the 16 week intervention]